On May 18, 2023, the Supreme Court issued its opinion in Amgen Inc. v. Sanofi, No. 21-757, affirming unanimously the Federal Circuit’s decision invalidating two of Amgen’s patents functionally claiming a genus of monoclonal antibodies that help reduce levels of low-density lipoprotein cholesterol (LDL, or “bad” cholesterol).